Idebenone Antagonizes P53-Mediated Neuronal Oxidative Stress Injury by Regulating CD38-SIRT3 Protein Level

Area of Science:

• Neuroscience
• Molecular Biology
• Biochemistry

Background:

• Oxidative stress contributes to neurodegenerative diseases by damaging cellular components.
• The neuroprotective mechanisms of Idebenone, an antioxidant, are not fully understood.
• Oxidative stress impacts Adp-ribosyl cyclase (CD38) and Silent message regulator 3 (SIRT3) expression, potentially affecting p53 deacetylation.

Purpose of the Study:

• To investigate the relationship between CD38, SIRT3, and p53 in Idebenone-treated, hydrogen peroxide-injured HT22 cells.
• To elucidate the neuroprotective pathway of Idebenone involving these key proteins.

Main Methods:

• HT22 cells were injured with hydrogen peroxide (H2O2) and treated with Idebenone.
• Apoptosis was assessed using flow cytometry and TUNEL staining.
• Protein expression levels of CD38, SIRT3, p53, acetylated p53 (p53Ac), and Caspase3 were analyzed.
• Bioinformatics methods were used to identify Idebenone's molecular target.
• NAD+/NADH ratios were measured to assess cellular metabolic state.

Main Results:

• Idebenone treatment reduced apoptosis and decreased p53 and Caspase3 expression in H2O2-injured HT22 cells.
• Bioinformatics identified CD38 as a target of Idebenone; Idebenone decreased CD38 expression and increased SIRT3 levels.
• An elevated NAD+/NADH ratio indicated Idebenone promotes SIRT3 expression.
• SIRT3 knockdown led to increased p53 acetylation, confirming SIRT3's role in p53 deacetylation.

Conclusions:

• Idebenone protects HT22 cells from oxidative stress by targeting CD38 to upregulate SIRT3, which then deacetylates p53, inhibiting apoptosis.
• This pathway highlights Idebenone's potential therapeutic value for reactive oxygen species-induced diseases, including Parkinson's and Alzheimer's disease.
• Idebenone may also help address defects in CD38-related disorders.